TOPK mediates immune evasion of renal cell carcinoma via upregulating the expression of PD-L1

Although anti-PD-L1 therapy has been used in the clinical treatment of renal cell carcinoma (RCC), a proportion of patients are not sensitive to it, which may be attributed to the heterogeneity of PD-L1 expression. Here, we demonstrated that high TOPK (T-LAK cell-originated Protein Kinase) expressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jinxin, Sun, Huimin, Fu, Meiling, Zheng, Zeyuan, Xu, Chunlan, Yang, Kunao, Liu, Yankuo, Xuan, Zuodong, Bai, Yang, Zheng, Jianzhong, Zhao, Yue, Shi, Zhiyuan, Shao, Chen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316654/
https://www.ncbi.nlm.nih.gov/pubmed/37404377
http://dx.doi.org/10.1016/j.isci.2023.107185

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10316654/
https://www.ncbi.nlm.nih.gov/pubmed/37404377
http://dx.doi.org/10.1016/j.isci.2023.107185

Ejemplares similares